People and Business News — 3/22
People News
Seqster PDM, Inc. announced the appointment of Bruno Villetelle, to its strategic advisory board.
Curebase has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board.
NNIT has appointed Camilla G. Møhl as its new SVP and Chief People, Communications and Marketing Officer.
ClinOne has named Andrea Valente as Chief Executive Officer.
Advanced Clinical announced that Dr. Andreas Amrein has joined the Executive Team as Senior Vice President of Asia-Pacific and Japan, as well as Managing Director for Europe and Canada.
MMS Holdings announced this week the addition of Dr. Robert Allen as Principal Medical Director to its Global Drug Safety and Pharmacovigilance team.
Total Diversity Clinical Trial Management announced Mark Hanley as a Board Member and Advisor.
Business News
Florence Healthcare announced that 285 million Americans now live within 25-miles of a Florence digital-workflow-equipped clinical research site.
Calyx announced its electronic data capture system has been selected by a leading pharmaceutical company to capture Real World Evidence data for a global, late-phase study.
Rho announced that it has been named the Autoimmune Diseases Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases.
Suvoda LLC launched a refreshed brand, to better reflect its leadership position as a global clinical trial technology company that specializes in highly complex studies, such as oncology, central nervous system, and rare disease.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
